Market Report Source

Overview

Austin Research Group’s Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on the profiled-disease; typically includes top-line information on:

• Epidemiology
• Patient Segmentation
• Clinical endpoints

The Trial TRAX brief also contains analysis of the clinical landscape with assessments including:

• % utilization of key clinical endpoints
• Number of ongoing trials (by phase of development)
• Key companies sponsoring clinical trials

The main body of the brief presents key data points from competitor clinical trials in a matrix format, enabling decision-makers the ability to quickly recall and analyze information on competitor studies. The brief’s reference-guide format is designed to provide decision makers with easy access to key intelligence on competitive clinical development programs. Primary data points include:

• Study Drug
• Mechanism of Action
• Company-Sponsor
• Phase of Development
• Number of Patients
• Study Design
• Primary Endpoints
• Study Start Date

Clients utilize the Trial TRAX briefing reports to:

• Monitor clinical development programs of competitors
• Quickly evaluate depth and breadth of competitive landscape
• Easy-to-use reference guide for analyzing competitor clinical trials
• Identify potential patient recruitment challenges
• Benchmark competitor clinical trial designs

Companies mentioned in the report:

• Amgen
• Biogen Idec
• Pfizer
• Eli Lilly
• Genentech
• Wyeth

Table of Contents

Section 1: Executive Summary
Rheumatoid Arthritis Disease Overview: Background, Epidemiology, and Severity
Clinical Endpoints Utilized in Rheumatoid Arthritis Trials
Overview of Clinical Landscape
Key Players in Rheumatoid Arthritis R&D

Section 2: Ongoing Clinical Trial in Rheumatoid Arthritis
Phase 1 Clinical Trial Details
Phase 2 Clinical Trial Details
Phase 3 Clinical Trial Details

Section 3: Appendix
Disclaimer
Report Licensing